P1300 EFFICACY AND SAFETY OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DCV+ASV) IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1B: RESULTS OF THE HALLMARK DUAL STUDY
Jia‐Horng Kao(National Taiwan University Hospital), M.P. Manns, Stuart Roberts, Fernando Bessone(National University of Rosario), Justin Kopit(Gdańsk Medical University), Misti Linaberry(Bristol-Myers Squibb (United States)), Stephanie Noviello(Novartis (United States)), William Sievert(Monash Health), Ira M. Jacobson(Cornell University), K.T. Yoon, Boris Yoffe(Baylor College of Medicine), June Heo, Cheng‐Yuan Peng(China Medical University), Eric Hughes(The University of Texas at San Antonio Health Science Center)
Cited by 9
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k